Eksperimentell transplantasjon for kreft

Forskningsgruppen undersøker levertranplantasjon som terapi for bestemte kreftarter, med mål om å tilby bedre pasienttilpasset behandling.

I ulike studier undersøker vi nytten av levertransplantasjon (Ltx) hos pasienter med inoperable levermetastaser fra kolorektal kreft, enkelte former for cholangiocarcinom og enkelte pasienter med levermetastaser fra uvealt malignt melanom.

SECA I-studien

Den første studien med levertransplantasjon hos pasienter med inoperable levermetastaser fra kolorektal kreft.  Resultatene viser en dramatisk forbedring i overlevelsen sammenlignet med behandlingsalternativet som ville være kjemoterapi.
Varighet: 2004 - 2011
Studieansvarlig: Aksel Foss

SECA II-studien

I denne studien vil vi undersøke om levertransplantasjon gir en høyere 5-års overlevelse sammenlignet med leverreseksjon hos pasienter som har fire eller flere operable levermetastaser. Vi vil også undersøke om vi kan identifisere pasienter med inoperable levermetastaser som oppnår en 5-års overlevelse etter levertransplantasjon på 70-90 %.
Varighet: 2014 - 2018
Studieansvarlig: Svein Dueland

MECA studien

Okulær melanom (OM) sprer seg til leveren i 90% av tilfellene. Leverreseksjon (fjerne deler av leveren) er livsforlengende og total overlevelse varierer 20-42% etter fem år. Det er kun publisert en rapport om levertransplantasjon (LT) hos en pasient med OM levermetastaser (LM). Denne pasienten hadde store mengder metastaser og døde åtte måneder etter lever transplantasjon.
I Norge har det vært et overskudd av donor lever og en institusjonell intensjon å utforske levertransplantasjon som behandling for metastaser. Planen er å inkludere 10 pasienter i en prospektiv pilot for ikke-resektabel OM LM (MECA-studien). Målet er å vurdere sikkerhet og potensialet for langsiktig overlevelse.
Studieansvarlig: Aksel Foss

Rapid studien

Levertransplantasjon hos pasienter med spredning til lever fra tykk- eller endetarmskreft.
Studieansvarlig: Pål-Dag Line

Utvalgte publikasjoner

  • Liver transplantation for nonresectable liver metastases from colorectal cancer. Annals of Surgery 2013 May;257(5):800-6.
  • Quality of life following liver transplantation in patients with liver metastases from colorectal carcinoma. Scandinavian Journal of Caring Sciences. 2012 Dec;26(4):713-9

Samarbeid

  • Institutt for kreftforskning, Universitetet i Oslo og Oslo universitetssykehus
  • Herlev Universitets sykehus, Danmark

Publikasjoner

  • Baumann U, Adam R, Duvoux C, Mikolajczyk R, Karam V, D'Antiga L, et al. Survival of children after liver transplantation for hepatocellular carcinoma. Liver Transpl. 2017 Dec 9;24(2):1–10.
  • Berntsen NL, Fosby B, Valestrand L, Tan C, Reims H, Schrumpf E, et al. Establishment of a surgical bile duct injection technique giving direct access to the bile ducts for studies of the murine biliary tree. Am J Physiol Gastrointest Liver Physiol. 2017 Dec 6;:ajpgi.00124.2017.
  • Grut H, Solberg S, Seierstad T, Revheim ME, Egge TS, Larsen SG, et al. Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. British Journal of Surgery. 2017 Nov 23.
  • Line PD, Hagness M, Solheim JM, Foss A, Dueland S: Liver transplantation for unresectable disease. In; de Santibañes E, Ardiles V, Alvarez F, Busnell VC, de Santibañes M (Eds.) Extreme Hepatic Surgery and Other Strategies. Increasing Resectability in Colorectal Liver Metastases. Springer Verlag 2017 ISBN 978-3-319-13896-1
  • Line P-D, Bjørnbeth BA. Improving the safety of associating liver partition and portal vein ligation for staged hepatectomy. Translational Cancer Research. 2017 Nov 5;6(3):S560–3.
  • Shi JH, Hammarström C, Grzyb K, Line PD. Experimental evaluation of liver regeneration patterns and liver function following ALPPS. BJS Open. John Wiley & Sons, Ltd; 2017 Oct 24;127:512–3.
  • Grut H, Dueland S, Line P-D, Revheim ME. The prognostic value of (18)F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging. 2017 Oct 12;4(Suppl 1):283.
  • Nordin A, Åberg F, Pukkala E, Pedersen CR, Storm HH, Rasmussen A, et al. Decreasing incidence of cancer after liver transplantation - A Nordic population-based study over three decades. Am J Transplant. 2017 Sep 19;50(Suppl 3):797.
  • Kleive D, Sahakyan MA, Berstad AE, Verbeke CS, Gladhaug IP, Edwin B, et al. Trends in indications, complications and outcomes for venous resection during pancreatoduodenectomy. Br J Surg. 2017 Aug 17;104(11):1558–67.
  • Lønning K, Midtvedt K, Bernklev T, Brunborg C, Andersen MH, Lippe von der N, et al. Changes in health related quality of life in older candidates waiting for kidney transplantation. Nephrology. 2017 Jul 22;:1–21.
  • Østensen AB, Sanengen T, Holter E, Line P-D, Almaas R. No effect of treatment with intravenous ganciclovir on Epstein-Barr virus viremia demonstrated after pediatric liver transplantation. Pediatric Transplantation. 2017 Jun 26;21(6):e13010–8.
  • Heldal K, Hartmann A, Lønning K, Leivestad T, Reisaeter AV, Line P-D, et al. Should patients older than 65 years be offered a second kidney transplant? BMC Nephrol. BioMed Central; 2017 Jan 11;18(1):13.
  • Chellappa S, Hugenschmidt H, Hagness M, Subramani S, Melum E, Line P-D, et al. CD8+ T Cells That Coexpress RORγt and T-bet Are Functionally Impaired and Expand in Patients with Distal Bile Duct Cancer. J Immunol. American Association of Immunologists; 2017 Jan 4;198(4):1600061–1739.
  • Vikum D, Nordøy I, Torp Andersen C, Fevang B, Line P-D, Kolrud FK, et al. A Young, Immunocompetent Woman with Small Bowel and Hepatic Mucormycosis Successfully Treated with Aggressive Surgical Debridements and Antifungal Therapy. Case Reports in Infectious Diseases. 2017;2017:1–4.
  • Dueland S, Guren TK, Boberg KM, Reims HM, Grzyb K, Aamdal S, Julsrud L, Line PD. Acute liver graft rejection after ipilimumab therapy. Ann Oncol. 2017 Oct 1;28(10):2619-2620. doi: 10.1093/annonc/mdx281. No abstract available. PMID: 28961840
  • Labori KJ, Lassen K, Hoem D, Grønbech JE, Søreide JA, Mortensen K, Smaaland R, Sorbye H, Verbeke C, Dueland S. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial. BMC Surg. 2017 Aug 25;17(1):94. doi: 10.1186/s12893-017-0291-1. PMID: 28841916
  • Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K. Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. ESMO Open. 2017 May 2;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017. PMID: 28761742
  • Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival. Acta Oncol. 2017 Jun;56(6):813-818. doi: 10.1080/0284186X.2017.1287951. Epub 2017 Feb 17. PMID: 28464745
  • Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K. Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial. Ann Surg Oncol. 2017 Jul;24(7):1916-1922. doi: 10.1245/s10434-017-5814-6. Epub 2017 Feb 21. PMID: 28224367
  • Labori KJ, Guren MG, Brudvik KW, Røsok BI, Waage A, Nesbakken A, Larsen S, Dueland S, Edwin B, Bjørnbeth BA. Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival.  Colorectal Dis. 2017 Aug;19(8):731-738. doi: 10.1111/codi.13622. PMID:28181384
  • Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G. Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. Oncoimmunology. 2016 Oct 18;5(11):e1232237. doi: 10.1080/2162402X.2016.1232237. eCollection 2016. PMID: 27999747
  • Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C, Peeters M, Ross P, Bridgewater J, Melichar B, Cascinu S, Saramak P, Michl P, Van Brummelen D, Zaniboni A, Schmiegel W, Dueland S, Giurescu M, Garosi VL, Roth K, Schulz A, Seidel H, Rajagopalan P, Teufel M, Childs BH. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Target Oncol. 2017 Feb;12(1):97-109. doi: 10.1007/s11523-016-0469-y. PMID: 27975152
  • Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH. Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy. Cancer Res Treat. 2017 Apr;49(2):374-386. doi: 10.4143/crt.2016.080. Epub 2016 Jul 28. PMID: 27488871
Publisert 23. okt. 2013 10:55 - Sist endret 9. juli 2018 09:43

Kontakt

Gruppeleder